Summit Trail Advisors LLC Sells 76,429 Shares of Precigen, Inc. (NASDAQ:PGEN)

Summit Trail Advisors LLC cut its position in Precigen, Inc. (NASDAQ:PGEN) by 73.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,100 shares of the biotechnology company’s stock after selling 76,429 shares during the quarter. Summit Trail Advisors LLC’s holdings in Precigen were worth $31,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PGEN. AQR Capital Management LLC boosted its stake in Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 18,097 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 16,486 shares during the period. SG Americas Securities LLC boosted its stake in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 13,823 shares during the period. Exchange Traded Concepts LLC boosted its stake in Precigen by 10.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 15,525 shares during the period. Finally, LexAurum Advisors LLC boosted its stake in Precigen by 13.8% in the 3rd quarter. LexAurum Advisors LLC now owns 274,489 shares of the biotechnology company’s stock valued at $260,000 after purchasing an additional 33,300 shares during the period. 33.51% of the stock is currently owned by institutional investors.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $1.98 on Friday. The stock has a market capitalization of $579.88 million, a PE ratio of -3.60 and a beta of 1.66. The business has a fifty day moving average price of $1.13 and a two-hundred day moving average price of $1.04. Precigen, Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $2.04.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PGEN. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Precigen in a report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Precigen currently has an average rating of “Hold” and a consensus target price of $7.00.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.